



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

3rd June, 2016

Corporate Relationship Department
The Bombay Stock Exchange Limited
Dalal Street, Fort
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) **Mumbai 400 051**

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Please find enclosed herewith the Press Release for your information.

Thanking you,

Yours faithfully,
For NATCO Pharma Limited

A handwritten signature in black ink that reads "M. Adinarayana".

M. Adinarayana
Company Secretary &
Vice President (Legal & Corp. Affairs)



Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

Ref:PR/003/2016

Press Release

NATCO receives USFDA tentative approval for Sorafenib Tablets, 200mg

Hyderabad, India, June 3rd, 2016

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announced today that its marketing partner, Mylan Inc. (Nasdaq:MYL), has received **a tentative approval** for its Abbreviated New Drug Application (ANDA) for Sorafenib Tablets, 200mg, with the U.S. Food and Drug Administration (USFDA). This product is the generic version of NEXAVAR[®], which is indicated for the treatment of certain types of cancers including unresectable hepatocellular carcinoma and advanced renal cell carcinoma.

NATCO and Mylan have filed an ANDA containing a Paragraph IV certification for this product. **NATCO** manufactures this product at its facility in Kothur, Mahaboobnagar District, Telangana State, India.

Bayer Healthcare LLC, Bayer Healthcare Pharmaceuticals Inc., and Onyx Pharmaceuticals Inc., sells Sorafenib Tablets, 200mg, under Brand name NEXAVAR[®], in the U.S. market. For the 12 months ending Dec. 31, 2015, NEXAVAR[®] had U.S. sales of approximately \$300 million. (SOURCE: Bayer's Annual Report)

Forwarded for favor of publication

For NATCO Pharma Limited

M. Adinarayana

M. Adinarayana
Company Secretary &
Vice President (Legal and Corp Affairs)